Phase II study of durvalumab plus olaparibin in patients with metastatic pancreatic cancer and DNA damage repair genes alterations
Grupo TTD > Comunicaciones > Phase II study of durvalumab plus olaparibin in patients with metastatic pancreatic cancer and DNA damage repair genes alterations
